Cellebrite DI Ltd. (NASDAQ:CLBT) Sees Significant Increase in Short Interest

Cellebrite DI Ltd. (NASDAQ:CLBT) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 1,170,000 shares, a growth of 13.6% from the December 15th total of 1,030,000 shares. Based on an average trading volume of 1,310,000 shares, the days-to-cover ratio is presently 0.9 days. Currently, 1.4% of the company’s stock are sold short.

Cellebrite DI Stock Down 0.9 %

Cellebrite DI stock traded down $0.20 during trading on Friday, hitting $22.78. The stock had a trading volume of 1,221,391 shares, compared to its average volume of 879,357. The stock’s 50 day moving average is $20.76 and its two-hundred day moving average is $17.60. Cellebrite DI has a 1 year low of $8.23 and a 1 year high of $23.50. The stock has a market cap of $4.69 billion, a price-to-earnings ratio of -14.70, a price-to-earnings-growth ratio of 3.18 and a beta of 1.46.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.05. The company had revenue of $106.90 million during the quarter, compared to analyst estimates of $102.06 million. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The firm’s revenue for the quarter was up 27.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.09 EPS. As a group, equities research analysts anticipate that Cellebrite DI will post 0.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on CLBT. Craig Hallum raised their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Needham & Company LLC boosted their target price on Cellebrite DI from $17.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. TD Cowen upped their target price on Cellebrite DI from $20.00 to $23.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Finally, JPMorgan Chase & Co. boosted their price objective on Cellebrite DI from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cellebrite DI currently has an average rating of “Buy” and a consensus price target of $20.57.

Institutional Trading of Cellebrite DI

Institutional investors have recently modified their holdings of the business. Janney Montgomery Scott LLC raised its holdings in Cellebrite DI by 30.0% during the 4th quarter. Janney Montgomery Scott LLC now owns 66,487 shares of the company’s stock valued at $1,465,000 after acquiring an additional 15,332 shares during the period. SG Americas Securities LLC boosted its stake in Cellebrite DI by 2,244.2% in the 4th quarter. SG Americas Securities LLC now owns 209,529 shares of the company’s stock worth $4,616,000 after purchasing an additional 200,591 shares during the period. Jackson Square Capital LLC purchased a new position in Cellebrite DI during the 4th quarter valued at about $1,596,000. Harbor Capital Advisors Inc. increased its position in shares of Cellebrite DI by 65.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 157,671 shares of the company’s stock valued at $3,473,000 after buying an additional 62,320 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Cellebrite DI by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company’s stock worth $7,202,000 after buying an additional 75,092 shares in the last quarter. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.